POWER OF
PRECISION.
WHY
PRECISION DIAGNOSTICS
PRECISION DIAGNOSTICS:
THE KEY TO ADVANCING PRECISION MEDICINE
The field of precision medicine has evolved rapidly
- < 250 personalized medicines are available1
- New drugs are being approved regularly1
Incorporating precision medicine into routine clinical care has been challenging
- Large and complex datasets
- Incomplete genomic insights
Advances in precision diagnostics can make everyday precision medicine a reality1
- Detect disease onset at its earliest stage
- Target treatments to those patients who will most likely benefit
- Increase effciency of the healthcare system2
References:
- www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/Research_Program_2021.pdf
2. Pennell NA, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1-9.
COMPREHENSIVE GENOMIC PROFILING:
EVOLVING THE STANDARD OF CARE
References:
- Nesline MK, et al. Oncologist uptake of comprehensive genomic pro le guided targeted therapy. Oncotarget. 2019;10(45):4616-4629.
- Kuo FC, et al. The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice. Blood. 2017;130(4):433-439.
- Shah D, et al. ASCO Connection. Hotspot testing versus next-generation sequencing for NSCLC. https://connection.asco.org/magazine/current-controversies-oncology/
hotspot-testing-versus-next- generation-sequencing-nsclc. Accessed 06/16/2021. - Hess JM, et al. Passenger hotspot mutations in cancer. Cancer Cell. 2019;36(3):288-301.e14.
COMPREHENSIVE GENOMIC PROFILING:
FACILITATES TARGETED THERAPY
Can help ensure patients receive targeted therapy, which can improve outcomes1
Hypothetical example
Reference:
- Sorich MJ, et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival bene t in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol. 2015;26(1):13-21.
COMPREHENSIVE GENOMIC PROFILING:
SAVES TIME AND COST
SAVES TIME AND COST
TIME TO RESULTS RECEIPT
SAVES TIME AND COST
TOTAL COST MEDICARE INSURED PATIENTS
- Pennell NA, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1-9.
WHO
WE ARE
OUR APPROACH TO NEXT-GENERATION SEQUENCING
SETS US APART
A complete picture
with comprehensive analysis of both hematologic and solid tumors
Cutting-edge technology
informed by an algorithm that is continually updated with new information as it becomes clinically relevant and validated
Cost-effective solution
with actionable reporting
that can inform decision-making
in everyday practice
OUR PEOPLE ARE OUR GREATEST ASSETS
DR. MAHER ALBITAR
FOUNDER, CEO OF
GENOMIC TESTING COOPERATIVE
Dr. Albitar has extensive experience in anatomic/clinical pathology, hematopathology, and molecular pathology.
He also has extensive business and administrative experience as an executive leader of large laboratories, board member, and director of large scientific and genomic diagnostic studies.
Dr. Albitar’s previous experience also includes his position as Senior Vice President, Chief Medical Officer, and Director of Research and Development at NeoGenomics.
OUR PEOPLE ARE OUR GREATEST ASSETS
DR. ALEX EWING
MEDICAL DIRECTOR,
ANTHOLOGY DIAGNOSTICS
Dr. Ewing is Chair, Department of Pathology, and Medical Director of the Laboratories at JFK University Medical Center, where he has served since 2003.
Dr. Ewing received his B.S. degree from Davidson College in 1993, and his M.D. degree from Wake Forest University School of Medicine in 1997.
He completed his residency in Anatomic and Clinical Pathology at Georgetown University Hospital in Washington, DC, in 2001, also serving as Chief Resident.
POWERED BY GENOMIC TESTING COOPERATIVE (GTC)
We’re proud to be at the forefront of meaningful change for
physicians and patients
- Founded in partnership with
Hackensack Meridian Health
and the GTC to bring
comprehensive genomic
profiling for cancer to the local
New Jersey community and
East Coast
- The first lab to utilize GTC’s
cooperative business model
to internalize their nextgeneration
sequencing
for oncology - Participating labs share
resources, best practices, and
data; and help each other with
publication studies
- Founded in partnership with
Hackensack Meridian Health
and the GTC to bring
comprehensive genomic
profiling for cancer to the local
New Jersey community and
East Coast
WHAT
WE DO
Comprehensive molecular profile
• All types of genomic changes (single nucleotide variants, insertions/deletions, copy number variations, fusions)
• Detection of minimal residual disease
• Treatment selection
• Surveillance monitoring for early recurrence
Quality results from small samples
Minimum sample requirements for comprehensive testing
• Bone marrow: 2 mL
• Fresh tissue: 5 microns
• Peripheral blood: 5 mL
Fast turnaround times
• 7 days for DNA
• 10 days for RNA
Clinically actionable reporting
• Customized treatment plans
• Confirmed by clinical pathologist
Variety of sample types supported
• Formalin-Fixed Para n-Embedded (FFPE)
• Peripheral blood
• Bone marrow
• Fresh tissue
Dedicated real-time support
• Expert team of pathologists dedicated to individual
treatment plans
• Physician-sta ed clinical support to help interpret
lab results
INFORMING CLINICAL DECISION-MAKING
Our testing provides the information that can help
make more informed clinical decisions regarding:
Making a
diagnosis
Identifying a
targeted treatment
Monitoring minimal
residual disease
Payers have potentially overlooked comprehensive genomic profiling as a sophisticated testing approach that informs complex clinical decision-making and enables a patient’s next best care option, be it drug therapy or no further treatment.
Reference:
- Reference: 1. Nesline MK, et al. Oncologist uptake of comprehensive genomic pro le guided targeted therapy. Oncotarget. 2019;10(45):4616-4629.
WHY
WE ARE DIFFERENT
STATE-OF-THE-ART INNOVATION
Machine/deep learning meets next-generation sequencing (NGS)
NGS
Utilizing revolutionary genomic sequencing methods
- Anthology Diagnostics is bringing new advances to this dynamic field with our comprehensive, cancer-specific DNA and RNA testing platforms
Co-Op
We work together to achieve more
- Our labs work together with physicians and patients to improve access to cutting-edge
healthcare - We perform on-site genomic sequencing and upload the data to GTC, which uses its algorithms to analyze
AI Machine Learning
Bringing computer science to laboratories
- Our artificial intelligence (AI) technology helps us sort through and curate large sets of data
- This allows us to quickly assess the impact of genomic alterations on a patient’s prognosis, diagnosis, and treatment response
Treatment Teams
World-class pathologists providing personalized treatment plans
- Utilizing the information gained through machine learning, our team reviews the complete genomic output, including all relevant genetic alterations
- Our team then creates individual treatment plans, which include personalized targeted therapies, immunotherapies, and clinical trial options
ACTIONABLE REPORTING
Simplified test reports with clear interpretation of results
- Provides precise diagnosis of disease and subclassification
- Identifies therapeutic options, including:
• FDA-approved therapies
• Therapies currently being investigated in clinical trials
• Off-label use of therapies approved for other indications - Informs clinical actions, including:
• Detection of minimal residual disease
• Treatment selection
• Surveillance monitoring for early recurrence - Customized treatment plan from world-renowned
clinical pathology team
GETTING
STARTED
GETTING STARTED
New customers will need to complete the New Client Information Form to establish an account
Once registered, opt in to our online portal to:
- Order Anthology Diagnostics–specific tests
- Fill out Test Requisition forms
- Easily search, sort, and review Anthology Diagnostics patient reports
Completed forms can be
- emailed to info@anthologydiagnostics.com or
- faxed to 732-321-7298
CLINICAL WORKFLOW
SIMPLE 3-STEP ORDERING PROCESS
GTC has simplified the process to incorporate
precision diagnostics into routine clinical care
Step 1: Understand the testing options
- Both solid and hematologic tumors have a variety of molecular profiling tests available
- Sample requirements will vary depending on chosen tests
Step 2: Complete the test requisition form*
- Patient information and history
- Patient diagnosis
- Specimen information
- Test selections
Step 3: Interpret the
final report
Your final report will include:
- Diagnosis of disease and
subclassification - Therapeutic options
- Customized treatment plan
*Once this form is complete, Genomic Testing Cooperative will ship a Collection Kit for tumor sample collection if needed.
BROAD ACCESS & REIMBURSEMENT
Covered by most major insurance plans
- Reimbursement rates vary by network
- Currently cover over 132 million lives
Current as of 7/11/2020
RESOURCES
Hematology
Profile- TAT
5-7 Days - Indications
MDS, CMML, AML, MPN (JAK2, CALR, MPL), MRD, lymphoma, multiple myeloma, other hematologic diseases
- - Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue - Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Liquid Biopsy
Hematology Profile- TAT
5-7 Days DNA - Indications
cfDNA - MDS, CMML, AML, MPN, lymphoma, MRD
- - Sample Type
Peripheral blood - Sample Requirements
Peripheral blood: 5-10 ml.
EDTA tube preferred
- - Results Reported
DNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Hematology Fusion /
Expression Profile- TAT
7-10 Days RNA - Indications
ALL hematologic neoplasms:
Fusion: BCR-ABL1, FIP1L1-PDGFRA, ETV6-RUNX1, PML-RARA, RUNX1-RUNX1T1, ALL-Ph-Like fusions
Expression: PD-L1, B-cell markers, T-cell markers, myeloid markers, KI67, MYC, BCL2, BCL6, BCL1, BCMA, PAX5
alternative splicing, Mutations in all 1400 genes - Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue - Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Hematology
Profile Plus- TAT
5-7 Days DNA
7-10 Days RNA - Indications
Classification and diagnosis of lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia
- - Sample Type
Bone marrow,
Peripheral blood,
Fresh tissue - Sample Requirements
Bone marrow: 2ml.
Peripheral blood: 5 ml.
EDTA tube preferred
FFPE: 1 H&E slide and 6-10 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Solid Tumor
Profile- TAT
5-7 Days - Indications
All solid tumors:
Mutations in 434 genes,
copy number variation and chromosomal structural abnormalities,
TMB, MSI
- - Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Solid Tumor Fusion / Expression Profile
- TAT
7-10 Days RNA - Indications
ALL Solid tumors:
Fusion: ALK, ROS1, RET, NTRK1/2/3, FGFR1/2/3/4, BRAF, CIC, EWSR1 and other sarcoma genes
Expression: PD-L1, MYC, CCND1, MET, FGFR1/2/3/4, Ki67,
ERBB2, MDM2
Alternative splicing: MET exon 14 skipping, EGFR vIII , NTRK
Mutations in all 1400 genes - Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Solid Tumor
Profile Plus- TAT
5-7 Days DNA
7-10 Days RNA - Indications
ALK, ROS1, RET, NTRK1/2/3, BRAF, CIC, EWSR1, PD-L1,
MET exon 14 skipping and various alternative splicing,
MET, HER2,
EGFR amplification,
PIK3CA, PTEN, AKT1 and RAS
- - Sample Type
FFPE - Sample Requirements
1 H&E slide and 6-8 unstained slides, 5-7 microns of tissue fixed with 10% NBF fixative - Results Reported
DNA+RNA - Diagnostic
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
Solid Tumor
Monitoring- TAT
5-7 Days DNA - Indications
Monitoring therapy,
resistance and relapse
- - Sample Type
Peripheral blood - Sample Requirements
Peripheral blood: 5-10 ml.
EDTA tube preferred - Results Reported
DNA - Monitoring
- Therapeutic
- Prognostic
- Heterogeneity
- Clinical Trial Matching
